Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 0/5 criteria met. Data as of 17/09/2026.
- ❌ Price trend failed
- ❌ Growth failed
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: 22.13%
Price change 2019 → 2020: -29.18%
Price change 2020 → 2021: 19.83%
Price change 2021 → 2022: -24.70%
Price change 2022 → 2023: -36.61%
Price change 2023 → 2024: 20.50%
Price change 2024 → 2025: 13.69%
Price change 2025 → 2026: -15.51%
Price change 2026 (year to date): -15.05%
Financial growth
Revenue CAGR (8 years): -1.71%
Earnings CAGR (8 years): -39.18%
Growth status: weak or negative trend (<1%/yr) in revenue and earnings.
Debt
Debt-to-equity ratio: 1.57
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 49.29
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 23.34% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="ALTA.PA" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Altarea SCA | 47.8 | 1.57 | +8.1 % | 🔒 |
| Argan S.A. | 6.5 | 0.74 | +13.5 % | – |
| Carmila S.A. | 6.8 | 0.80 | +44.6 % | – |
| Icade S.A. | – | 1.13 | +0.1 % | – |
| Mercialys | 16.3 | 2.94 | +3.1 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|